The price of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) closed at $137.59 in the last session, down -0.11% from day before closing price of $137.74. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 614130 shares were traded.
Ratios:
We take a closer look at NBIX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.86. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.12.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $136.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Delaet Ingrid sold 272 shares for $137.30 per share. The transaction valued at 37,346 led to the insider holds 7,507 shares of the business.
Delaet Ingrid sold 5,000 shares of NBIX for $725,320 on Mar 21 ’24. The Chief Regulatory Officer now owns 7,507 shares after completing the transaction at $145.06 per share. On Mar 14 ’24, another insider, BENEVICH ERIC, who serves as the Chief Commercial Officer of the company, sold 75,000 shares for $139.38 each. As a result, the insider received 10,453,417 and left with 40,778 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 13.70B and an Enterprise Value of 13.10B. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 56.62, and their Forward P/E ratio for the next fiscal year is 20.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.26 while its Price-to-Book (P/B) ratio in mrq is 6.08. Its current Enterprise Value per Revenue stands at 6.94 whereas that against EBITDA is 36.59.
Stock Price History:
Over the past 52 weeks, NBIX has reached a high of $148.37, while it has fallen to a 52-week low of $89.04. The 50-Day Moving Average of the stock is 137.21, while the 200-Day Moving Average is calculated to be 119.00.
Shares Statistics:
According to the various share statistics, NBIX traded on average about 879.19K shares per day over the past 3-months and 1.04M shares per day over the past 10 days. A total of 98.70M shares are outstanding, with a floating share count of 96.92M. Insiders hold about 2.60% of the company’s shares, while institutions hold 93.80% stake in the company. Shares short for NBIX as of Mar 15, 2024 were 2.48M with a Short Ratio of 2.83, compared to 2.18M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.50% and a Short% of Float of 2.90%.
Earnings Estimates
The company has 18 analysts who recommend its stock at the moment. On average, analysts expect EPS of $1 for the current quarter, with a high estimate of $1.77 and a low estimate of $0.21, while EPS last year was -$0.79. The consensus estimate for the next quarter is $1.19, with high estimates of $1.67 and low estimates of $0.89.
Analysts are recommending an EPS of between $5.72 and $3.84 for the fiscal current year, implying an average EPS of $4.8. EPS for the following year is $6.29, with 19 analysts recommending between $8.51 and $4.58.
Revenue Estimates
According to 25 analysts, the current quarter’s revenue is expected to be $514.49M. It ranges from a high estimate of $546M to a low estimate of $493M. As of the current estimate, Neurocrine Biosciences, Inc.’s year-ago sales were $409.26M, an estimated increase of 25.70% from the year-ago figure. For the next quarter, 23 analysts are estimating revenue of $546.04M, an increase of 22.10% less than the figure of $25.70% in the same quarter last year. There is a high estimate of $591.3M for the next quarter, whereas the lowest estimate is $528M.
A total of 27 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.32B, while the lowest revenue estimate was $2.14B, resulting in an average revenue estimate of $2.21B. In the same quarter a year ago, actual revenue was $1.89B, up 17.30% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $2.57B in the next fiscal year. The high estimate is $3.78B and the low estimate is $2.26B. The average revenue growth estimate for next year is up 16.30% from the average revenue estimate for this year.
